A testing dose was unnecessary, Novartis believed, given that valsartan 320mg (160mg twice a day) had been tested in heart failure and with a 1:1 ratio with sacubitril. "I had nothing to learn ...

Because the proposed generic drug accused of infringement was a “complex” of bonded valsartan and sacubitril, the patentee Novartis needed to urge and had successfully urged that ...

but in order for Novartis Access to make a long-term impact, we need to drive it locally." The 15 medicines included in the initiative include three branded medicines: valsartan for hypertension ...

Novartis, an innovative medicines company, announced that the company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that ...